Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00162513|
Recruitment Status : Withdrawn (PI is no longer work at Hadassah)
First Posted : September 13, 2005
Last Update Posted : April 28, 2011
Donors with CM will be solicited from a waiting list of patients awaiting BMT from the waiting list of MUD searches.
Maximally matched donor will be searched for each eligible CML patient with a goal in mind to find other patients with CML that share both class I and class II determinants. Sharing of one class I II will be considered eligible for participation in the study. Peripheral blood and PBMC from the donors will be isolated, washed and irradiated.
The cells will be injected into the consenting patients intracutaneously at 2 weeks intervals for a total of 6 injections.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Myeloid Leukemia||Biological: Allogeneic tumor cell vaccine||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia|
|Study Start Date :||December 2006|
- Investigate the feasibility of allogeneic tumor cell vaccine for patients with resistant CML.
- To induce immunity against a putative bcr/abl peptide bound to MHC identical class I, II or preferably both.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00162513
|Hadassah Medical Organization|
|Jerusalem, Israel, 91120|
|Principal Investigator:||Shimon Slavin, MD||Hadassah Medical Organization|